UK Government's infatuation with gene therapy goes back a long way—it's not healthy

Oct 04, 2022

∙ Paid

Government celebrations

Late last month I posted on how UK Government celebrated a £7.1 million funding award for Oxford Biomedica (OXB), a contract development and manufacturing organisation (CDMO) in gene therapy. As the consultant commissioned to help frame the application for the funding call, titled: Advanced Manufacturing Supply Chain Initiative (AMSCI), I was invited to the celebration at OXBs headquarters in Cowley, Oxford.

Read the full story here:

INSIDE PHARMA

My first-hand experience working with the company developing and manufacturing the AstraZeneca ‘vaccine’

AstraZeneca did not develop or manufacture the adenovirus vaccine I was first involved with the company that developed and manufactured the AZ marketed gene therapy product in 2013. It was in the days of the coalition Government, and it related to a funding call sponsored by…

3 years ago · 11 likes · 3 comments · Hedley Rees

I mention in the post “Also involved in the project was UK Government’s (through Innovate UK) Cell & Gene Therapy Catapult (CGTC), albeit OXB dealt with them directly on technical and science considerations.”

That direct connection continued after I left the project, as the CGTC received funding to help implement the project.

It’s only now I’m joining up the dots

It’s only in recent months, as I have looked back and begun to join up the dots, that the picture is emerging.

This ‘success’ was the foundation for what became UK Government’s…

INSIDE PHARMA

UK Government's infatuation with gene therapy goes back a long way—it's not healthy

Government celebrations

It’s only now I’m joining up the dots

This post is for paid subscribers